Nektar Therapeutics Inc (NASDAQ:NKTR) shares eased after the Amikacin Inhales study in intubated and mechanically ventilated patients with Gram-negative pneumonia failed to meet primary endpoint of superiority.
In a statement, Bayer AG said that INHALE, a global Phase III clinical study programme, did not demonstrate superiority versus standard of care plus aerosolized placebo.
The primary endpoint, as well as secondary endpoints were similar in both treatment arms.
Efficacy and safety analyses to be published in due course
Amikacin Inhale is the development name of an integrated drug-device combination, consisting of a specially formulated Amikacin Inhalation Solution and a proprietary Synchronized Inhalation System with a vibrating mesh nebulizer.
Efficacy and safety analyses from this study will be published in due course.
Amikacin Inhale (BAY 41-6551) is the development name for an investigational integrated drug-device combination product, in development by Bayer, comprised of a specially formulated Amikacin Inhalation Solution with Nektar Therapeutics' proprietary Synchronized Inhalation System.
Nektar shares were down 1.83% at US49.09.